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Objective: To compare the effectiveness of a non-pharmacological multidisciplinary face-to-face self-
management treatment program with a telephone-based program on daily function in patients with
generalized osteoarthritis (GOA).
Design: A pragmatic single-blind randomized clinical superiority trial involving 147 patients clinically
diagnosed with GOA, randomly allocated to either a 6 week non-pharmacological multidisciplinary face-
to-face treatment program comprising seven group sessions or a 6 week telephone-based treatment
program comprising two group sessions combined with four telephone contacts. Both programs aimed
to improve daily function and to enhance self-management to control the disease. The programs criti-
cally differed in mode of delivery and intensity. Daily function (primary outcome) and secondary out-
comes were assessed at baseline, 6, 26 and 52 weeks. Data were analyzed using linear or logistic
multilevel regression models corrected for baseline, sex and group-wise treatment.
Results: No differences in effectiveness between both treatment programs were observed on the primary
outcome (group difference (95% CI): 0.03 (0.14, 0.07)) or on secondary outcome measures, except for a
larger improvement in pain in the face-to-face treatment group (group difference (95% CI): 1.61 (0.01,
3.21)). Within groups, signiﬁcant improvements were observed on several domains, especially in the
face-to-face group. However, these beneﬁts are relatively small and unlikely to be of clinical importance.
Conclusions: We found no differences in treatment effect between patients with GOA who followed a
non-pharmacological multidisciplinary face-to-face self-management program and those who received a
telephone-delivered program. Besides, our ﬁndings demonstrated limited beneﬁts of a self-management
program for individuals with GOA.
Dutch Trial Register trial number: NTR2137.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: N. Cuperus, Department of
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ternational. Published by Elsevier LIntroduction
Osteoarthritis (OA) can affect multiple joints, but is most com-
mon in the hand, spine and the weight-bearing joints i.e., the hip
and knee1,2. In recent years, clinically relevant OA subpopulations
or so called phenotypes have been classiﬁed whereby different
joint groups are generally seen as distinct phenotypes1,3,4. A
commonly used and widely accepted phenotype is generalized
osteoarthritis (GOA)3,4, describing a subset of patients withtd. All rights reserved.
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tions have been described in the literature, however no agreed and
validated deﬁnition is available so far5. Most deﬁnitions of GOA
include at least three joints or joint groups, but there is little
agreement on the necessity or appropriateness of including a
speciﬁc joint or combination of joints. It has been suggested that
individuals with GOAmight represent a relatively large subgroup of
patients with OA. In knee OA, approximately 50% of patients can be
classiﬁed as GOA 6e8.
Several international guidelines for the management of OA are
available emphasizing the effectiveness of non-pharmacological,
non-surgical interventions, such as education, self-management,
weight reduction and exercise therapy9e14. However, these
guidelines all focus on single joint involvement (i.e., hand, hip or
knee), without considering the involvement of multiple joints.
Recently, the Osteoarthritis Research Society International (OARSI)
was the ﬁrst to publish recommendations for the non-surgical
management of OA for several subpopulations, including multi-
ple joint OA (i.e., OA in other joints in addition to the knee)12.
However, due to the limited research on the management of
multiple joint OA, the authors only considered balneotherapy
(deﬁned as the use of baths containing thermal mineral waters)
appropriate for patients with multiple joint OA, whereas no other
recommendations could be formulated. Yet, it is likely that rec-
ommendations for hip and knee OA also apply for individuals with
GOA.
Considering the substantial group of patients with GOA, the lack
of knowledge on the non-pharmacological management of GOA
and the high physical and psychological burden associated with
GOA7,8,13,15,16, the development and evaluation of a treatment
program for patients with GOA is warranted. Therefore, our
research group systematically developed a non-pharmacological,
multidisciplinary face-to-face treatment program for individuals
with GOA based on recommendations for the management of hip
and knee OA14 and tailored to the needs of patients with GOA17.
Treatment components of the program included education, self-
management and exercises. Besides, a less intensive telephone-
based treatment program was developed since increasing evi-
dence shows telephone-based interventions to be cost-efﬁcient18
and to improve symptoms and promote lifestyle changes19,20. The
aim of the current study was to compare the effectiveness of both
treatment programs on daily function during the ﬁrst year after
treatment. We hypothesized the face-to-face treatment program to
be superior in effect on daily function, since this program is more
extensive and more strictly supervised.
Methods
Study design
This study was a pragmatic parallel group, single-blind ran-
domized clinical superiority trial comparing the effectiveness of a
6 week non-pharmacological multidisciplinary supervised face-to-
face treatment program with a 6 week telephone-based treatment
program on daily function in patients with GOA. The effectiveness
over 1 year was examined. Details of the trial development and
design have been published previously17. The protocol adhered to
the CONSORT guidelines for non-pharmacological interventions21.
The study was performed at the outpatient rheumatology de-
partments of the Sint Maartenskliniek Nijmegen and Woerden, the
Netherlands from January 2010 to April 2014 and was approved by
the local ethics committee (CMO region Arnhem, Nijmegen) and
registered in the Dutch Trial Register (trial number NTR2137). All
participants signed informed consent prior to the baseline data
collection.Setting and participants
During an outpatient visit, patients clinically diagnosed with
GOA and referred by their rheumatologist for treatment were
invited for a screening visit to consider eligibility for the trial. Pa-
tients were included when: (1) having at least two objective signs
indicating OA in 2 joint areas on the basis of the patient's medical
record (objective signs included:malalignment, crepitation, limited
range of motion, palpable osteophytes or nodules or radiographic
signs including the presence of joint space narrowing and/or
osteophytes); (2) having complaints in 3 out of 8 joint areas (i.e.,
feet, knees, hips, lumbar spine, neck, shoulders, elbows and hands);
(3) being limited in the performance of daily activities (Health
Assessment Questionnaire Disability Index (HAQ-DI) score  0.5);
and (4) motivated to alter their lifestyle and willing to participate in
a group (assessed by a standardized set of questions). Excluded
were patients who were: (1) diagnosed with another rheumatic
disease; (2) awaiting surgery; (3) already participated unsuccess-
fully in a self-management program; (4) having psychosocial
problems interfering with the scope of the treatment; (5) incapable
of coming to the hospital; or (6) unable to write and or understand
the Dutch language.
Interventions
The overall goals of both treatment programs were to improve
daily function and to enhance self-management skills to control
the disease. The face-to-face treatment was provided by a multi-
disciplinary team comprising a physical therapist, occupational
therapist, specialized rheumatology nurse and dietician. The
telephone-based treatment was provided by a specialized rheu-
matology nurse and physical therapist. The most critical differ-
ences between both treatments were the mode of care delivery,
the number of involved healthcare providers, the number of group
sessions and the number of sessions including an exercise pro-
gram. For an overview of the content of both programs see
Appendix 1. The healthcare providers were trained in techniques
of motivational interviewing22 and were specialized in treating
patients with musculoskeletal disorders and teaching self-
management principles. To standardize both programs, slide pre-
sentations for all sessions and manuals for healthcare providers
and patients were used. Protocol adherence of healthcare pro-
viders was maintained by meetings during the trial.
Face-to-face treatment group
The multidisciplinary face-to-face program comprised six ther-
apeutic group sessions (6e8 patients and 2e4 h) and a group
evaluation delivered during 6 weeks, supervised by a physical
therapist. In the ﬁrst session information about the treatment
programwas given, expectations were discussed and patients ﬁlled
in activity and diet diaries. Information about GOA, pain manage-
ment and medication was also provided in this session. Addition-
ally, patients participated in a general exercise program to improve
the quality of movement and posture (i.e., walking, sitting) and to
implement exercises in the home situation. This exercise program
was continued in session two (standing, kneeling, lifting) and three
(stair climbing, lying). Information on physical activity and activity
pacing was given in session two and information on food con-
sumption was given in sessions three and four. Furthermore, in
session three patients were asked to set personal goals regarding
pain management, physical activity and activity pacing which were
closely monitored and discussed in the next three sessions. Besides,
patients participated in a speciﬁc exercise program based on the
principles of graded activity and tailored to the patient's health
problems in sessions four, ﬁve and six. Acceptance as a strategy to
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patients with other strategies to manage their symptoms, intro-
duction lessons of Tai Chi, Brisk walking and hydrotherapy were
given. The program was evaluated in the ﬁnal session and future
personal goals were formulated.
Telephone-based treatment group
Patients allocated to the telephone-based treatment attended
two face-to-face group sessions (6e8 patients) with a duration
of 2e2.5 h and were further monitored by four individual
telephone contacts (15e30 min per contact) with a specialized
rheumatology nurse. In the ﬁrst group session, patients were
educated about the program, OA, pain management, medication,
physical activity, activity pacing, food consumption and accep-
tance of the disease. Besides, patients completed activity and
diet diaries. During the individual telephone contacts, patients
set personal goals regarding pain management, physical activity
and activity pacing which were closely monitored and discussed.
The second group session included an exercise program tailored
to the patient's health problems to improve the quality of
movement and posture and to implement the exercises in the
home situation. Besides, patient's personal goals were discussed.
The treatment program was evaluated during the ﬁnal telephone
contact.
Randomization and blinding
Patients were allocated to the treatment groups (allocation ratio
1:1) by an independent person using a computer generated
randomization sequence table consisting of randomly varied block
sizes (2e6). Assignments were communicated by e-mail to the
outpatient clinics and patients were informed by mail. This study
has a partly blinded design as due to the nature of the interventions
neither patients nor healthcare providers could be blinded for
allocation. The assessor (NC) was blinded for randomization and
allocation and the statistical analyses were performed blindly.
Participants were instructed not to disclose details about their
group allocation with the assessor. The allocation of healthcare
providers was done on basis of availability.
Measurements and outcomes
Primary and secondary outcome measures were collected prior
to the start of the treatment (i.e., baseline), after ﬁnishing the
treatment (i.e., 6 weeks) and 26 and 52 weeks after starting the
treatment. Demographic data were collected at baseline.
Primary outcome measure
The primary outcome measure was daily function measured
with the Dutch consensus HAQ-DI23. The HAQ-DI examines difﬁ-
culties with the performance of 20 daily activities (classiﬁed into 8
categories) scored from 0 (without any difﬁculty) to 3 (unable to
do). The highest scores of each category are summed and averaged
resulting in a disability index ranging from 0 (no disability) to 3
(very severe disability).
Secondary outcome measures
Health related quality of life (HRQoL) was measured with the
Short Form 36 Health Survey (SF-36), comprising eight areas of
health status and a physical (PCS) and mental component sum-
mary score (MCS)24. Pain was assessed using the SF-36 bodily pain
subscale. Fatigue was measured with the eight-itemed “Subjective
Fatigue” subscale of the Checklist Individual Strength (CIS)25. The
patient speciﬁc complaints questionnaire (PSK) was administered
to elicit patient speciﬁc and relevant activity limitations26. Patientsidentiﬁed the three most important GOA related functional limi-
tations and scored the severity on a 0e10 scale, with higher total
scores indicating more severe limitations. Self-efﬁcacy was
assessed with the General Self-Efﬁcacy Scale (GSES)27 and illness
cognitions were measured using the subscales acceptance and
helplessness of the Illness Cognitions Questionnaire (ICQ)28. Pain-
related fear for moving was measured with the Tampa scale for
kinesiophobia (TSK) with total scores ranging from 17 to 68
(higher scores indicating more fear)29. Physical activity levels were
measured with the Short Questionnaire to Assess Health
enhancing physical activity (SQUASH) and presented as the
number of patients meeting the Dutch recommendation for
physical activity (moderate physical activity for >30 min for ﬁve
days/week)30. Moreover, patients rated their health status on a
visual analog scale (EQ VAS) ranging from 0 (worst imaginable
health status) to 100 (best imaginable health status). After ﬁn-
ishing the treatment, change in daily function was rated on a 7-
point Likert transition question ranging from completely recov-
ered to vastly worsened. Costs were also assessed, but these re-
sults will be presented elsewhere.
Study endpoints
The primary endpoint was the difference in mean HAQ-DI score
between both treatment groups i.e., the average score obtained
from the 6, 26 and 52 week time points (long-term effect). The
6 week time point of the HAQ-DI provided a secondary endpoint.
Other secondary endpoints were the between group differences of
the secondary outcome measures and the within group differences
of all outcome measures. Furthermore, as there is no validated
outcome measure to asses the health status of patients with GOA,
we evaluated both programs with a responder analysis using a set
of self-constructed responder criteria17 adapted from the
OMERACT-OARSI knee and hip responder criteria31. Patients were
classiﬁed as responder if  3 of the following 6 areas improved
by  20% (average from the 6, 26 and 52 week time points):
physical function (PSK), pain (SF-36), fatigue (CIS), physical activity
(SQUASH), acceptance (ICQ) and patient global assessment (PGA)
(EQ VAS).
Statistical analysis
We estimated that a sample size of 170 patients was needed to
provide a power of 80% to show superiority of the face-to-face
treatment by at least 0.26 points on the HAQ-DI32, assuming a
standard deviation (SD) of 0.66, a signiﬁcance level of 0.05 and a
15% drop-out rate17.
Data were analyzed using Stata/IC 13.1. Missing data were esti-
mated using multiple imputation (MI) by changed equation in or-
der to preserve power and reduce bias33,34. A total of 20 imputed
data sets were predicted based on all other observed variables.
Primary analyses were done according to the intention-to-treat
(ITT) principle35. Secondary analysis included per-protocol anal-
ysis excluding major protocol violations (i.e., patients who either
discontinued treatment, crossed over to the other group or missed
>3 sessions). Descriptive statistics were used to describe the
characteristics of the study population and to explore baseline
comparability. Data were analyzed with a multilevel mixed linear
regression model with the mean scores obtained from the 6, 26 and
52 week time points as dependent variable and treatment group,
sex and baseline value as covariates. In order to account for the
group-wise treatment, groupwas included as random effect. Scores
obtained immediately after treatment were also evaluated using
the same multilevel mixed linear regression model. Within group
changes were evaluated by analyzing the mean changes scores
Fig. 1. Flow diagram.
N. Cuperus et al. / Osteoarthritis and Cartilage 23 (2015) 1267e12751270
Table I
Baseline characteristics of participants allocated to the face-to-face and telephone-
based treatment group
Face-to-face
treatment (n ¼ 75)
Telephone-based
treatment (n ¼ 72)
Age, years; mean (SD) 61 (8) 59 (8)
Female; n (%) 64 (85) 61 (85)
Body Mass Index, kg/m2;
mean (SD)
28 (5) 28 (5)
Currently employed; n (%) 28 (37) 27 (38)
Number of symptomatic joint
areas; median (IQR)
5 (4e6) 5 (4e6)
Localization of symptoms; n (%)
Upper extremities
(shoulder, elbow, hand)
68 (91) 66 (92)
Neck/lumbar spine 54 (72) 53 (74)
Lower extremities
(hip, knee, foot)
72 (96) 69 (96)
Combination of upper and
lower extremities
65 (87) 63 (88)
Daily function, HAQ-DI (0e3);
mean (SD)
1.27 (0.50) 1.26 (0.49)
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number of responders were analysed similar to the continuous
outcomes using multilevel mixed logistic regression and were
presented as odds ratios. No statistical adjustment was made for
multiple testing.Results
Participant's ﬂow diagram is presented in Fig. 1. A total of 236
(70%) patients were considered eligible for the trial of whom 158
(67%) were enrolled. Main reasons not to participate were having a
preference for the face-to-face treatment (n ¼ 46; 59%) or lacking
conﬁdence towards the telephone-based treatment (n ¼ 24; 31%).
Due to time constraints, we needed to stop the inclusion after 158
patients out of the targeted 170 patients were enrolled. No differ-
ences were found between the eligible patients who did not
participate and the study population with regard to age, whereas
there were relatively less women in the group of eligible patients
(72% vs 85%, P ¼ 0.01). The majority of participants (n ¼ 116; 73%)
were included in the Maartenskliniek Nijmegen. Eighty-one par-
ticipants were allocated to the face-to-face treatment and 77 to the
telephone-based treatment. Six patients from the face-to-face
group and ﬁve from the telephone group were lost before the
baseline measurement meaning that data from 147 participants
were available for the ITT analysis. These drop-outs can be
explained by the time between inclusion and start of the treatment
(up to 6 weeks) due to the group-wise treatment. The percentage ofTable II
Baseline data, mean changes from baseline (95% CI) and mean differences (95% CI) in ch
Face-to-face treatment
(n ¼ 75)
D 95% CI
Daily function (HAQ-DI)
Baseline; mean (SD) 1.27 (0.50)
D 6 weeks 0.03 (0.11, 0.05)
D average 1 year 0.06 (0.14, 0.02)
* Results are described as intention-to-treat.
y Multilevel mixed linear regression analyses corrected for baseline values, sex and grmissing data on the primary outcome was 0%, 7%, 12% and 14% at
baseline, 6, 26 and 52 weeks, respectively.
Baseline characteristics of the study population are presented in
Table I. The majority was female, nearly 90% of patients reported
symptoms in both the upper and lower extremities and the mean
(SD) HAQ-DI score was 1.27 (0.50) for the face-to-face group and
1.26 (0.49) for the telephone-based treatment group. Therewere no
relevant differences in baseline characteristics between groups. A
total of 19 healthcare providers were involved.
Primary endpoint
Patients in the face-to-face treatment group showed a larger
improvement in daily function over 1 year follow-up compared to
the patients in the telephone-based treatment group, however this
difference was not statistically signiﬁcant (mean group difference
HAQ-DI (95% CI): 0.03 (0.14, 0.07)). (Table II). The limits of the
95% CI do not reach the predeﬁned relevant difference in treatment
effect of 0.26 points.
Secondary endpoints
At the 6 week time point of the HAQ-DI, a small, non-signiﬁcant
difference in effectiveness between groups was observed (mean
group difference (95%CI): 0.01 (0.10, 0.13)). The upper and lower
conﬁdence limits exclude a clinically important difference in
treatment effect. A small signiﬁcant difference between groups was
observed for pain at the long term in favor of the face-to-face
treatment program, indicating that this program was more effec-
tive in reducing pain that the telephone-based program (mean
group difference (95% CI): 1.61 (0.01, 3.21)) (Table III). Directly after
treatment, signiﬁcantly fewer patients in the face-to-face group
met the self-reported Dutch recommendation for physical activity
compared to the telephone group (odds ratio (95% CI): 0.32 (0.11,
0.97)). Within groups, no signiﬁcant improvements were found on
our primary outcome measure. On several secondary outcome
measures signiﬁcant, but relatively small improvements were
observed at the short and long-term, especially in the face-to-face
group. After 1 year, 17 (22%) participants in the face-to-face treat-
ment group and 13 (18%) participants in the telephone-based group
fulﬁlled the responder criteria (odds ratio (95% CI): 1.22 (0.50,
3.00)) (Table IV).
Per-protocol analysis
Per-protocol analysis of the primary endpoint was performed
excluding eight protocol violators i.e., three participants in the face-
to-face group (crossed-over to the telephone-based treatment
group n ¼ 2, discontinued treatment n ¼ 1) and ﬁve participants in
the telephone-based treatment group (crossed over to the face-to-
face treatment group n¼ 2, missed > 3 sessions n¼ 2, discontinuedange scores between groups on the primary outcome measure*
Telephone-based treatment
(n ¼ 72)
D 95% CI Group differencey (95%CI)
1.26 (0.49)
0.06 (0.15, 0.03) 0.01 (0.10, 0.13)
0.02 (0.11, 0.06) 0.03 (0.14, 0.07)
oup-wise treatment.
Table III
Baseline data, mean changes from baseline (95% CI) and mean differences (95% CI) in change scores between groups on secondary outcome measures*
Face-to-face treatment (n ¼ 75) Telephone-based treatment (n ¼ 72) Group differencey (95% CI)
D 95% CI D 95% CI
Pain (SF-36)
Baseline; mean (SD) 39.60 (7.31) 40.45 (5.81)
D 6 weeks 3.19 (1.53, 4.85) 0.96 (0.76, 2.67) 1.82 (0.15, 3.80)
D average 1 year 2.83 (1.32, 4.33) 0.76 (0.71, 2.23) 1.64 (0.06, 3.22)
Patient speciﬁc function (PSK)
Baseline; mean (SD) 19.81 (5.51) 19.88 (4.17)
D 6 weeks 1.16 (2.44, 0.13) 1.53 (¡2.78, ¡0.28) 0.19 (1.45, 1.82)
D average 1 year 1.87 (¡2.93, ¡0.81) 1.43 (¡2.56, ¡0.29) 0.49 (1.87, 0.89)
Fatigue (CIS)
Baseline; mean (SD) 36.12 (7.23) 36.13 (7.52)
D 6 weeks 1.08 (3.28, 1.11) 1.04 (2.76, 0.69) 0.32 (2.81, 2.17)
D average 1 year 2.03 (¡3.76, ¡0.29) 1.10 (2.73, 0.52) 1.09 (2.95, 0.78)
Physical function (PCS SF-36)
Baseline; mean (SD) 37.65 (6.65) 37.17 (7.33)
D 6 weeks 2.25 (0.64, 3.85) 1.58 (0.11, 3.04) 0.89 (1.09, 2.86)
D average 1 year 1.58 (0.08, 2.81) 1.13 (0.32, 2.58) 0.49 (1.15, 2.12)
Mental function (MCS SF-36)
Baseline; mean (SD) 47.59 (10.31) 47.96 (10.96)
D 6 weeks 0.34 (1.85, 2.52) 0.82 (1.57, 3.21) 0.37 (3.36, 2.63)
D average 1 year 1.97 (0.12, 3.81) 0.21 (1.87, 2.29) 1.74 (0.42, 3.90)
Acceptance (ICQ)
Baseline; mean (SD) 14.52 (3.82) 14.86 (4.21)
D 6 weeks 0.93 (0.01, 1.87) 1.17 (0.32, 2.02) 0.29 (1.41, 0.84)
D average 1 year 1.36 (0.61, 2.12) 0.93 (0.17, 1.70) 0.33 (0.58, 1.24)
Helplessness (ICQ)
Baseline; mean (SD) 12.65 (3.70) 12.87 (3.32)
D 6 weeks 0.41 (1.18, 0.35) 0.48 (1.24, 0.28) 0.10 (1.12, 0.91)
D average 1 year 0.61 (1.26, 0.05) 0.56 (1.26, 0.13) 0.21 (1.05, 0.63)
Self-efﬁcacy (GSES)
Baseline; mean (SD) 31.13 (4.48) 31.06 (4.43)
D 6 weeks 0.21 (1.46, 1.04) 0.03 (1.24, 1.31) 0.11 (1.79, 1.58)
D average 1 year 0.28 (0.65, 1.21) 0.44 (1.51, 0.63) 0.84 (0.44, 2.12)
Kinesiophobia (TSK)
Baseline; mean (SD) 36.60 (7.65) 36.79 (7.05)
D 6 weeks 1.34 (3.27, 0.58) 1.91 (3.89, 0.06) 0.49 (2.24, 3.23)
D average 1 year 1.41 (2.95, 0.12) 1.05 (2.70, 0.60) 0.48 (2.52, 1.56)
PGA (EQ VAS)
Baseline; mean (SD) 53.84 (17.59) 53.42 (14.70)
D 6 weeks 8.43 (3.67, 13.20) 5.22 (0.83, 9.61) 3.26 (1.14, 7.67)
D average 1 year 6.59 (2.63, 10.55) 3.73 (0.06, 7.51) 3.18 (0.32, 6.68)
Physical activity (SQUASH)z
Baseline; n (%) 54 (72) 50 (70)
6 weeks; n (%) 50 (67) 58 (80) 0.32 (0.11, 0.97)x
1 year; n (%) 56 (75) 48 (67) 1.55 (0.65, 3.74)
Values in bold represents the signiﬁcant improvement/difference, P < 0.05.
* Results are described as intention-to-treat.
y Multilevel mixed linear regression analyses corrected for baseline values, sex and group-wise treatment.
z Number of participants (%) meeting recommendation for physical activity.
x Multilevel mixed logistic regression corrected for baseline values, sex and group-wise treatment, presented as odds ratios with associated conﬁdence interval.
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primary endpoint did not change (mean group difference (95%
CI): 0.04 (0.14, 0.07)).
Treatment adherence and adverse effects
Themean number of sessions participants attended was 6.6 (out
of 7) in the face-to-face group and 5.5 (out of 6) in the telephone-
based treatment group. We did not systematically assess adverse
effects, though patients were encouraged to report adverse effects
to the supervised healthcare professional. However, no adverse
effects related to the treatment programs were reported.
Discussion
This is the ﬁrst study on the effectiveness of a self-
management program for patients clinically diagnosed withGOA. We compared the effectiveness of two modes of therapy
delivery i.e., face-to-face vs telephone. Based on the results, there
is insufﬁcient evidence of an important difference in effect on
daily function between both groups. The results indicate absence
of evidence because the limits of the 95% CI do not cover the
predeﬁned relevant change of 0.26 points36. Furthermore, we
found no signiﬁcant differences in effectiveness between both
groups on the secondary outcomes, except for pain, the face-to-
face program was more effective in reducing pain at the long-
term. Within groups, signiﬁcant improvements were observed
on several domains, especially in the face-to-face treatment
group, although these beneﬁts are relatively small and unlikely to
be of clinical importance.
The observed small within group changes indicate an insufﬁ-
cient content of our treatment programs to achieve important
changes. Nevertheless, both programs comprised numerous treat-
ment elements that should be included in self-management
Table IV
Patients classiﬁed as responder for both treatment groups including odds ratios (95% CI)*
Face-to-face treatment (n ¼ 75) Telephone-based treatment (n ¼ 72) Odds ratio (95% CI)
Physical function (PSK) 20 (27) 17 (23) 1.28 (0.51, 3.21)
Pain (SF-36) 15 (20) 9 (12) 1.78 (0.69, 4.63)
Fatigue (CIS) 17 (22) 10 (14) 1.73 (0.66, 4.55)
Physical activity (SQUASH) 28 (37) 27 (38) 0.98 (0.45, 2.13)
Acceptance (ICQ) 23 (31) 22 (30) 1.05 (0.50, 2.27)
PGA (EQ VAS) 26 (34) 23 (32) 1.05 (0.47, 2.33)
Respondersy 17 (22) 13 (18) 1.22 (0.50, 3.00)
* Results are the numbers (percentage) unless indicated otherwise.
y Patients are considered responder if  3 of the areas presented in the table improved by  20%.
N. Cuperus et al. / Osteoarthritis and Cartilage 23 (2015) 1267e1275 1273programs as recommended in international guidelines for the
management of OA, like education, exercises and goal-setting10,37.
Probably, our programs addressed too much treatment elements
what might have hampered patients to pick up relevant informa-
tion for themselves. In order to achieve important changes in daily
function, it might be more beneﬁcial to include fewer treatment
elements. Increasing evidence supports the existence of only small
effects of OA self-management programs as reported in systematic
reviews38,39 and clinical guidelines10,37. Nevertheless, the impor-
tance of self-management is uniformly recognized in international
clinical guidelines in order to manage the disease effective-
ly10,11,13,37.It is therefore conceivable that recommendations
regarding self-management are based on clinical expertise and
patient values rather than on research evidence.
The choice of our primary outcome measure could be argued.
To date, there is a signiﬁcant heterogeneity in outcome measures
to evaluate OA self-management interventions and no validated
outcome measure is available39. Usually, main outcome measures
are pain and/or physical function39. However, self-management
programs are often not intended to only reduce pain or
improve physical function, but typically target on multiple do-
mains of daily living. Since there are no validated outcome
measures for clinical improvement in GOA, we chose the HAQ-DI
as primary outcome measure in the current study. However, our
interventions also targeted other dimensions relevant in GOA,
such as pain, fatigue, physical activity and acceptance. We
therefore evaluated our treatment programs with a responder
criteria set adapted from the OMERACT-OARSI responder criteria31
including the areas our interventions aimed to address. Future
research is needed to understand which outcomes are most
relevant to assess the effectiveness of self-management programs
in GOA.
Interestingly, during the inclusion period we observed that
many patients preferred the face-to-face treatment program and
were somewhat reluctant towards the telephone-based treatment.
Ninety percent of the eligible patients who declined to participate
did so because they preferred the face-to-face treatment. This
preference can be supported by a study examining the acceptability
of face-to-face, internet and telephone treatment delivery in pri-
mary care, showing the highest level of interest in face-to-face
treatment delivery40.
There are some important limitations that need to be
addressed. First, this study was developed as a pragmatic trial
implemented in daily clinical practice, so due to pragmatic con-
siderations we did not include a control group receiving no
treatment (e.g., waiting list). Second, this study involved patients
clinically diagnosed with GOA referred for rehabilitation which
might hamper the generalizability of our ﬁndings to other OApopulations. In the absence of a widely accepted and validated
deﬁnition of GOA, we used a pragmatic deﬁnition. Future research
is needed to determine an appropriate deﬁnition for clinical and
research use5. Third, as we did not make statistical adjustments for
multiple testing, there is a risk of positive results arising by chance
alone (type 1 error), whereas the small loss of power might have
increased the chance of a type 2 error. The inclusion proceeded at
a lower pace than expected as many patients declined to partici-
pate because they preferred the face-to-face treatment group. So,
due to time constraints we needed to stop the inclusion after 158
out of 236 patients agreed to participate. Finally, we did not
measure adherence to homework assignments in order to ensure
blinding to group assignment of the assessor who was responsible
for the data collection. The success of blinding was however not
evaluated.
In this clinical trial we demonstrated no evidence of impor-
tant differences in treatment effect between patients with GOA
who followed a non-pharmacological multidisciplinary face-to-
face self-management program and those who received a
telephone-based treatment program. Furthermore, both treat-
ment programs showed small signiﬁcant improvements on
several domains, however these are unlikely to be of clinical
importance. We also observed that many participants preferred
face-to-face treatment delivery above telephone delivery. The
results imply that the choice of treatment delivery can be based
on the patients and healthcare providers preferences, costs or
the availability of facilities and/or healthcare systems. Further-
more, our ﬁndings contribute to the increasing evidence of the
limited effect of self-management programs for patients with
OA. Future research is needed to understand which outcomes
are most relevant to assess the effectiveness of GOA self-
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Appendix 1. Content of a non-pharmacological face-to-face treatment program and a telephone-based treatment program for
patients with GOA.
Session Face-to-face treatment Telephone-based treatment
Content of the session Health care provider Content of the session Health care provider
1  60 min group education on the treatment
program, discussion of expectations and information
on activity and food consumption diaries
PT  60 min group education on the
treatment program, GOA, pain management,
pain, medication, physical (in)activity,
activity pacing, food consumption and
acceptance of the disease
SN
 90 min group education on GOA, pain management,
pain and medication
SN  60 min formulating personal goals regarding
pain management, physical activity and/or
activity pacing
SN
 60 min general exercise program to improve the quality
of movement and to implement exercises in the home
situation
OT & PT
2  60 min group education on the beneﬁts of physical
activity and negative consequences of inactivity
PT  15 min individual monitoring of personal
goals via telephone
SN
 60 min group education on activity pacing and
discussion of the activity diaries
OT
 60 min general exercise program to improve the
quality of movement and to implement exercises in the
home situation
OT & PT
 60 min Tai-Chi PT
3  60 min group education on food consumption D
 60 min general exercise program to improve the
quality of movement and to implement exercises in the
home situation
OT & PT
 60 min formulating personal goals regarding
pain management, physical activity and/or activity
pacing
PT
4  60 min group education on food consumption
and discussion of the food consumption diaries
D  30 min individual monitoring of personal
goals via telephone
SN
 30 min Brisk walking (walking at a fast pace) PT
 60 min group-based monitoring and discussion of
personal goals
PT
 60 min speciﬁc exercise program tailored to the
patient's individually health problems to implement
the exercises in the home situation
OT
5  60 min group education on acceptance of the disease
and discussion of starting points to implement this in the
home situation
SN  60 min group-based monitoring and
discussion of personal goals
SN
 60 min speciﬁc exercise program tailored to the
patient's individually health problems to implement the
exercises in the home situation
PT  60 min speciﬁc exercise program tailored
to the patient's individually health problems
to implement the exercises in the home
situation
SN & PT
 60 min group-based monitoring and discussion of
personal goals
OT
6  60 min group-based monitoring and discussion of
personal goals
PT  20 min setting future goals and evaluating the
treatment program via telephone
SN
 30 min hydrotherapy PT
 60 min speciﬁc exercise program tailored to the
patient's individually health problems to implement
the exercises in the home situation
OT
7  120 min setting future personal goals and evaluating
the treatment program
OT & PT  20 min individual monitoring of personal
goals via telephone
SN
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